Antithrombin III during High-Dose Cytosine Arabinoside Therapy with or without Asparaginase
- 1 January 1986
- journal article
- research article
- Published by S. Karger AG in Acta Haematologica
- Vol. 75 (2) , 96-99
- https://doi.org/10.1159/000206094
Abstract
Fourteen patients with hematologic neoplasia (11 acute myeloid leukemias, 2 non-Hodgkin’s lymphomas and 1 blast crisis of chronic myeloid leukemia) who underwent high-dose cytosine arabinoside (HIDARAC) therapy with or without sequential asparaginase (ASNase) were investigated in order to evaluate liver toxicity and a possible decrease in antithrombin III (AT III) plasma level. AT III was found decreased only in patients who received ASNase, whereas HIDARAC alone did not influence AT III levels. It is pointed out that a single dose of ASNase seems to be sufficient to induce a decrease in AT III. A mild and transient liver toxicity due to HIDARAC therapy does not seem to be of any clinical relevance.Keywords
This publication has 7 references indexed in Scilit:
- TREATMENT OF POOR RISK ACUTE-LEUKEMIA WITH SEQUENTIAL HIGH-DOSE ARA-C AND ASPARAGINASE1984
- HIGH-DOSE CYTOSINE-ARABINOSIDE THERAPY FOR REFRACTORY LEUKEMIA1983
- Fatal Pulmonary Embolism and Antithrombin III Deficiency in Adult Lymphoblastic Leukaemia during L-Asparaginase TherapyActa Haematologica, 1983
- Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginaseCancer, 1982
- A PILOT-STUDY OF HIGH-DOSE 1-BETA-D-ARABINOFURANOSYLCYTOSINE FOR ACUTE-LEUKEMIA AND REFRACTORY LYMPHOMA - CLINICAL-RESPONSE AND PHARMACOLOGY1982
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979
- Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH)Thrombosis Research, 1977